SCHEMBL20355086

SCHEMBL20355086

O=S(=O)(Nc1cc2c(cc1F)OC(F)(F)O2)c1c[nH]c2cc(Br)ccc12

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ACLY P53396 3/20 0.35
▸ BRD4 O60885 5/20 0.35
▸ CYP2A6 P11509 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ VSIR Q9H7M9 1/20 0.34
▸ HTR6 P50406 1/20 0.33
▸ GHSR Q92847 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ NMT1 P30419 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29559701 1.00 ALOX15 (0.36) ALOX15TSHRACLYBRD4CYP2A6
SCHEMBL20339120 0.87 CCR2 (0.40) TSHRACLY
SCHEMBL21545882 0.85 TDO2 (0.38) ACLYKMT2A
SCHEMBL29560107 0.85 MAPT (0.40) ACLYKMT2AMAPT
SCHEMBL20354694 0.85 MAPT (0.40) ACLYKMT2AMAPT
SCHEMBL20340303 0.85 ACLY (0.41) ACLYIDO1
SCHEMBL20354693 0.84 ACLY (0.42) ALOX15TSHRACLYCYP2A6KMT2A
SCHEMBL30286687 0.84 ACLY (0.42) ALOX15TSHRACLYCYP2A6KMT2A
SCHEMBL20355203 0.83 CYP2A6 (0.33) ACLYBRD4CYP2A6KMT2AHTR6
SCHEMBL29560099 0.83 CYP2A6 (0.33) ACLYBRD4CYP2A6KMT2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2022-05-31 — — US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALOX15 617/4885TSHR 2860/4885ACLY 3879/4885
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ALOX15 617/4885TSHR 2860/4885ACLY 3879/4885
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ALOX15 617/4885TSHR 2860/4885ACLY 3879/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALOX15 617/4885TSHR 2860/4885ACLY 3879/4885
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ALOX15 617/4885TSHR 2860/4885ACLY 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback